Why the study?
Arrhythmias frequently occur and contribute to postoperative morbidity and mortality after paediatric cardiac surgery, but literature assessing the safety and efficacy of common antiarrhythmics in this population is limited.
Do antiarrhythmics improve safety and efficacy in children <18 years of age after cardiac surgery?
RCT (n=317)
Double-blind
Randomized
Do antiarrhythmics improve safety and efficacy in children <18 years of age after cardiac surgery?
Evidence supporting the use of antiarrhythmics in children after cardiac surgery is limited and heterogeneous, highlighting the need for standardized pragmatic randomized trials.
Sparse evidence on antiarrhythmic safety and efficacy after pediatric cardiac surgery; leaves open need for prospective trials.
BACKGROUND: Arrhythmias after paediatric cardiac surgery occur frequently and contribute to postoperative morbidity and mortality. There is limited literature assessing the safety and efficacy of common antiarrhythmics administered in this population. METHODS: We systematically searched PubMed and EMBASE for literature on antiarrhythmic use in children <18 years of age after cardiac surgery from 2000 to 2024. Two reviewers independently screened abstracts and then reviewed full-text manuscripts to determine eligibility. RESULTS: We identified 28 studies of 3,752 patients across 11 different antiarrhythmics: flecainide, procainamide, esmolol, landiolol, propranolol, amiodarone, sotalol, dexmedetomidine, digoxin, ivabradine, and magnesium. Most studies were small, with 17 enrolling fewer than 100 children. Only eight studies were randomised, 16 were retrospective, 12 were prospective, and one was multicenter. Safety and efficacy endpoints varied widely, limiting our ability to combine data for meta-analysis. Overall, evidence supporting the use of these drugs in children after cardiac surgery was limited. CONCLUSION: Although antiarrhythmics are commonly used in children after cardiac surgery, randomised trials with standardised endpoints to guide choice of therapy are lacking. Pragmatic trials to generate real-world data should be considered to further evaluate the safety and efficacy of various antiarrhythmics in this population.
No takes yet. Share an insight, caveat, or question.
Sullenger et al. (2026) conducted an RCT in Supraventricular tachycardia (n=317). Landiolol vs. Placebo was evaluated on Heart rate decrease (>20% decrease in heart rate or a heart rate <100 bpm or at least intermittent cessation of the arrhythmia).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: